Mirati Therapeutics

Traded on the St. Petersburg Stock Exchange
Mirati Therapeutics, Inc. is a clinical-stage oncology company developing product candidates to address the genetic, epigenetic and immunological promoters of cancer.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Mirati Therapeutics balance sheet

Report period2018 2019 2020 2021 2022 Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Mirati Therapeutics cash flows

Report period2017 2018 2019 2020 2021 2022
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Mirati Therapeutics multipliers

Report period2018 2019 2020 2021 2022 Q3 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Mirati Therapeutics profitability

Report period2018 2019 2020 2021 2022 Q3 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Mirati Therapeutics assets
Mirati Therapeutics cash flows
Mirati Therapeutics news
09.10.2023
Bristol Myers is buying Mirati Therapeutics for $5.8 billion, or $58 per share. Deal is expected to close in the first half of 2024.
Source: {source} pictogram news.bms.com
Pictogram next
05.05.2022
Mirati Therapeutics' GAAP loss for 3 months of 2022 was $188.386 million, up 38.8% from $135.68 million in the previous year. Revenues were $709 thousand. The company did not earn revenues a year earlier.
Source: {source} pictogram ir.mirati.com
Pictogram next
01.03.2022
Mirati Therapeutics' GAAP loss for 2021 was $581.784 million, up 62.5% from $357.937 million in the previous year. Revenue increased 5.4 times to $72.092 million from $13.398 million a year earlier.
Source: {source} pictogram ir.mirati.com
Pictogram next
09.11.2021
Mirati Therapeutics' GAAP loss for 9M 2021 was $382.164 million, up 48.8% from $256.85 million in the previous year. Revenue increased 6.1 times to $71.793 million from $11.69 million a year earlier.
Source: {source} pictogram ir.mirati.com
Pictogram next
All Mirati Therapeutics news
General information
Company nameMirati Therapeutics
Tags#biotechnology
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-332-3410
Mailing address9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Websitewww.mirati.com
Information disclosurewww.sec.gov